Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study
Martín Arranz, María Dolores; García-Ramírez, Laura; Martín Arranz, Eduardo; Montero Vega, Dolores; Rueda García, José Luis; Sánchez-Azofra, María; Poza Cordón, Joaquín; Noci Belda, Jesús; Martínez-Meco, Tamara Verges; San Miguel, Paula Blanco.
Rev. esp. enferm. dig
; 115(8): 444-449, 2023. ilus, tab
Artículo
en Inglés
| IBECS (España) | ID: ibc-223638
Background and
aims:
response to the SARS-CoV-2 vaccine can be altered in patients with immune-mediated diseases, such as inflammatory bowel disease, and in patients under immunosuppressive treatment. The aims of this study were to evaluate the serologic response to the SARS-CoV-2 vaccine in patients with inflammatory bowel disease, to analyze the influence of immunosuppressive drugs on response, and to describe any adverse events in this population.Methods:
this was a prospective study that included adult patients with inflammatory bowel disease. Baseline characteristics, concomitant treatments and previous COVID-19 symptoms were collected. Patients underwent serological testing before the first and after the second vaccine dose.Results:
a total of 265 patients were consecutively included. Patients received one of the following vaccines messenger RNA vaccines from Pfizer/BioNTech and Moderna; and adenovirus vaccines from AstraZeneca and Janssen. All adverse events were mild, and the most frequent was injection site pain in 141 (86 %) patients. The seroconversion rate according to the treatment that patients were receiving was 100 % for those without treatment, 92.5 % for patients treated with mesalazine, 90.3 % for those receiving immunomodulators, 88.9 % for patients with biological monotherapy and 92.5 % for patients on combined treatment. The generation of antibodies according to the vaccine administered was Pfizer 92.9 %, Moderna 93.3 %, AstraZeneca 98.4 %, and Janssen 12.5 %.Conclusion:
the antibody response after vaccination against SARS-CoV-2 is high in patients with inflammatory bowel disease. However, patients treated with immunosuppressive or biologic drugs had a lower response. Adverse events were frequent, but not serious (AU)
Biblioteca responsable:
ES1.1
Ubicación: ES15.1 - BNCS
Documentos relacionados